This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum
The Kerry Hotel
September 10–11, 2024 | Shanghai, ChinaSeptember 16–17, 2024 | Virtual

Janet Xiao
Partner at Morrison Foerster


Dr. Janet Xiao, Ph.D., J.D., specializes in world-wide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Chambers USA and Chambers Global recognize her as being highly sought after for patent prosecution and strategy mandates by innovators from around the world.

Dr Xiao’s clients range from large multinational biopharmaceutical companies, such as Celgene, Genentech, and Bayer Healthcare, to emerging startup companies worldwide. She advises her clients on patent matters relating to various technologies including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals.

Recognized for her deep understanding of the industry and knowledge of IP, Janet is highly sought after for developing and strengthening her clients’ complex patent portfolios to maximize their commercial value and success. She is instrumental on the strategy development for multibillion-dollar patent portfolios for pharmaceutical clients, and adds tremendous value by combining her creative legal skills, keen business acumen, and solid foundation in science. As impressed clients noted to Chambers, “Janet’s work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge.”

Dr. Xiao works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, as well as marketing and manufacturing clearance forbiopharmaceutical products. She works with some of the world’s most sophisticated biopharmaceutical companies and investors in assessing potential risks and devising preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is most notable for her deep knowledge about patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Dr. Xiao works synergistically with patent litigators in the event of legal challenges by third-party competitors or vice versa, and is frequently called upon to represent clients in litigation and post-grant proceedings.

Agenda Sessions

  • Panel discussion: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023


At this event